Posted in aging, bioengineering, biological, biotech/medical, disruptive technology, DNA, genetics, health, life extension, science | Leave a Comment on 10 companies that want to make chemotherapy easier for patients — Bioquark Inc.
The idea of storing digital data in DNA seems like science fiction. At first glance, it might not seem obvious that a molecule can store data. The term “data storage” conjures up images of physical artifacts like CDs and data centers, not a microscopic molecule like DNA. But there are a number of reasons why DNA is an exciting option for information storage.
The status quo
We’re in the midst of a data explosion. We create vast amounts of information via our estimated 17 billion internet-connected devices: smartphones, cars, health trackers, and all other devices. As we continue to add sensors and network connectivity to physical devices we will produce more and more data. Similarly, as we bring online the 4.2 billion people who are currently offline, we will produce more and more data.
PCG-1α therapy shows promise in treating age-related decline.
It is always a good idea to look closely at the biochemistry involved in any potential Alzheimer’s disease therapy that shows promise in mouse models. There is perhaps more uncertainty for Alzheimer’s than most other age-related conditions when it comes to the degree to which the models are a useful representation of the disease state in humans — which might go some way towards explaining the promising failures that litter the field. In the research here, the authors are aiming to suppress a step in the generation of amyloid-β, one of the proteins that aggregates in growing amounts and is associated with brain cell death in Alzheimer’s disease. They achieve this goal using gene therapy to increase the level of PGC-1α, which in turn reduces the level of an enzyme involved in the production of amyloid-β. Interestingly, increased levels of PGC-1α have in the past been shown to produce modest life extension in mice, along with some of the beneficial effects to health associated with calorie restriction.
Quote:
Time to get the toothbrush out and brush for longevity!
For decades, research has suggested a link between oral health and inflammatory diseases affecting the entire body — in particular, heart attacks and strokes.
The results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD®), show statistically significant reductions in dental plaque and inflammation throughout the body. Inflammation throughout the body is accurately measured by high sensitivity C-reactive protein (hs-CRP), a sensitive marker for future heart attacks and strokes. These results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD®, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.
In this trial, all randomized subjects were given the same brushing protocol and received a 60-day supply of toothpaste containing either Plaque HD® or an identical non-plaque identifying placebo toothpaste. To assess dental plaque, all subjects utilized a fluorescein mouth rinse, and intraoral photographs were taken under black light imaging. For hs-CRP, levels were measured by an independent laboratory using an enzyme linked immunosorbent assay.
A recent newspaper article under the headline “High street eye test can provide early indication of dementia” highlighted yet another complex connection between the eye and the brain.
This important eye-brain interface is still being researched and many disciplines are now working together to make fresh findings. But while most of us know that regular physical activity and eating healthily can help maintain or improve our well-being, few are aware of the importance of feeding our eyes with the right kind of light. Indeed, not experiencing the right quality and quantity of light could have adverse effects on hormonal changes, sleep patterns and may even be linked to obesity.
Could this finally help suppress and maybe even eliminate MS, Dystonia, Parkinson and other central nervous system disfunctions?
Last year, a team of Harvard University researchers revealed that they created a wire mesh doctors can inject into the brain to help treat Parkinson’s and other neurological diseases. They already successfully tested it on live mice, but now that technology is ready for the next stage: human testing. The mesh made of gold and polymers is so thin, it can coil inside a syringe’s needle and doesn’t need extensive surgery to insert. Once it’s inside your head, it merges with your brain, since the mesh has spaces where neurons can pass through.
A part of it needs to stick out through a small hole in your skull so it can be connected a computer. That connection is necessary to be able to monitor your brain activity and to deliver targeted electric jolts that can prevent neurons from dying off. By preventing the death of neurons, which triggers spasms and tremors, the device can be used to combat Parkinson’s and similar diseases. Eventually, the wire mesh could come with an implantable power supply and controls, eliminating the need to be linked to a computer.
The team believes their creation also has a future in mental health, since it can deliver a more targeted treatment for conditions like depression and schizophrenia than medications can. They’ll definitely find out more once human trials begin, and it sounds like it could take place in the near future. According to MIT’s Technology Review, the researchers have begun working with doctors at Massachusetts General Hospital and will soon perform experiments on patients with epilepsy.
Researchers have made the breakthrough of couch potatoes’ dreams with a new drug that mimics some of the most important effects of exercise. Scientists from Deakin University in Melbourne published their findings in Cell Reports earlier this week, showing that overweight mice who were given the drug no longer showed signs of cardiovascular disease.
The first of 50 patients to complete a trial for a new HIV treatment in the UK is showing no signs of the virus in his blood.
The initial signs are very promising, but it’s too soon to say it’s a cure just yet: the HIV may return, doctors warn, and the presence of anti-HIV drugs in the man’s body mean it’s difficult to tell whether traces of the virus are actually gone for good.
That said, the team behind the trial – run by five British universities and the UK’s National Health Service – says we could be on the brink of defeating HIV (human immunodeficiency virus) for real.
